The promise
to effectively
treat cancer
The promise
to effectively
treat
cancer
to effectively
treat
cancer
Company Highlights
Novel Technology
Novel MIRP™ technology to generate a
family of immuno-recruitment drugs for
multiple cancers
family of immuno-recruitment drugs for
multiple cancers
Promising Programs
Ongoing Phase I/II for solid tumors
Collaboration with ROCHE
to combine with Atezolizumab
Collaboration with ROCHE
to combine with Atezolizumab
Active pipeline
DSP107 - Phase I/II
DSP105 - IND Q4 2021
TSP - Multiple future candidates in R&D
DSP105 - IND Q4 2021
TSP - Multiple future candidates in R&D
Growing Market
Immuno-therapeutics market
to grow to
$56.5B by 2025
to grow to
$56.5B by 2025
Solid IP Portfolio
12 families
2 granted patents in US and ROW
10 pending patents worldwide
2 granted patents in US and ROW
10 pending patents worldwide
Strong Leadership
Seasoned management team
and KOL support: technology inventor,
Prof. Mark Tykocinski
and KOL support: technology inventor,
Prof. Mark Tykocinski
Contact Us
KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com